Zinbryta
Active Ingredient(s): DaclizumabFDA Approved: * May 27, 2016
Pharm Company: * BIOGEN
Category: Immunosuppressive
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[2][3][1] Contents 1 Medical uses 1.1 Discontinued use... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.1 Discussion
Dosage List
Related Brands
Drugs with the same active ingredientsPopular Topics
Zinbryta (daclizumab)
2 REPLIES
My husband spent seven weeks in the hospital, seriously ill. A major contributing factor is believed to be the Zinbryta ...